Aug 03, 2026
by
Michael Mahmoudi, MD - Y Sotomi, et al; Lancet 2026; 408:440-452
1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial